Your browser doesn't support javascript.
loading
Temporal trends in heart failure medication prescription in a population-based cohort study.
Uijl, Alicia; Vaartjes, Ilonca; Denaxas, S; Hemingway, Harry; Shah, Anoop; Cleland, J; Grobbee, Diederick; Hoes, Arno; Asselbergs, Folkert W; Koudstaal, Stefan.
Afiliación
  • Uijl A; Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands a.uijl@umcutrecht.nl.
  • Vaartjes I; Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Denaxas S; Institute of Health Informatics, University College London, London, UK.
  • Hemingway H; Health Data Research UK, London, UK.
  • Shah A; Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Cleland J; Institute of Health Informatics, University College London, London, UK.
  • Grobbee D; Health Data Research UK, London, UK.
  • Hoes A; The National Institute for Health Research University College London Hospitals Biomedical Research Centre, University College London, London, UK.
  • Asselbergs FW; Alan Turing Institute, London, UK.
  • Koudstaal S; Institute of Health Informatics, University College London, London, UK.
BMJ Open ; 11(3): e043290, 2021 03 02.
Article en En | MEDLINE | ID: mdl-33653753
OBJECTIVE: We examined temporal heart failure (HF) prescription patterns in a large representative sample of real-world patients in the UK, using electronic health records (EHR). METHODS: From primary and secondary care EHR, we identified 85 732 patients with a HF diagnosis between 2002 and 2015. Almost 50% of patients with HF were women and the median age was 79.1 (IQR 70.2-85.7) years, with age at diagnosis increasing over time. RESULTS: We found several trends in pharmacological HF management, including increased beta blocker prescriptions over time (29% in 2002-2005 and 54% in 2013-2015), which was not observed for mineralocorticoid receptor-antagonists (MR-antagonists) (18% in 2002-2005 and 18% in 2013-2015); higher prescription rates of loop diuretics in women and elderly patients together with lower prescription rates of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers, beta blockers or MR-antagonists in these patients; little change in medication prescription rates occurred after 6 months of HF diagnosis and, finally, patients hospitalised for HF who had no recorded follow-up in primary care had considerably lower prescription rates compared with patients with a HF diagnosis in primary care with or without HF hospitalisation. CONCLUSION: In the general population, the use of MR-antagonists for HF remained low and did not change throughout 13 years of follow-up. For most patients, few changes were seen in pharmacological management of HF in the 6 months following diagnosis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antagonistas de Receptores de Angiotensina / Insuficiencia Cardíaca Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: BMJ Open Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antagonistas de Receptores de Angiotensina / Insuficiencia Cardíaca Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: BMJ Open Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido